Altuğ Güner

Quick facts

Phase 2 pipeline

• Anti-TNF agents · Immunology
  Anti-TNF agents work by binding to and inhibiting tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine involved in systemic inflammation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Altuğ Güner portfolio CI brief
• Altuğ Güner pipeline updates RSS